Aimmune Therapeutics, Inc. (NASDAQ:AIMT) – Analysts at Wedbush lowered their Q3 2017 earnings per share (EPS) estimates for shares of Aimmune Therapeutics in a research report issued to clients and investors on Monday. Wedbush analyst L. Moussatos now expects that the biotechnology company will post earnings per share of ($0.72) for the quarter, down from their previous forecast of ($0.69). Wedbush currently has a “Ourperform” rating and a $42.00 price target on the stock. Wedbush also issued estimates for Aimmune Therapeutics’ Q4 2017 earnings at ($0.83) EPS, FY2017 earnings at ($2.72) EPS, FY2018 earnings at ($3.50) EPS, FY2019 earnings at ($3.58) EPS, FY2020 earnings at ($1.31) EPS and FY2021 earnings at $2.78 EPS.

AIMT has been the topic of several other research reports. ValuEngine lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 27th. Zacks Investment Research upgraded Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research note on Tuesday, June 13th. Piper Jaffray Companies set a $38.00 price target on Aimmune Therapeutics and gave the company a “buy” rating in a research note on Thursday, July 27th. Finally, BidaskClub lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $33.00.

COPYRIGHT VIOLATION NOTICE: “Q3 2017 EPS Estimates for Aimmune Therapeutics, Inc. (AIMT) Decreased by Wedbush” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/16/q3-2017-eps-estimates-for-aimmune-therapeutics-inc-aimt-decreased-by-wedbush.html.

Aimmune Therapeutics (NASDAQ:AIMT) opened at 19.31 on Wednesday. The company’s 50-day moving average price is $20.90 and its 200-day moving average price is $20.00. Aimmune Therapeutics has a 12-month low of $12.38 and a 12-month high of $27.31. The firm’s market capitalization is $975.83 million.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by $0.01.

Large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC increased its stake in Aimmune Therapeutics by 10.1% in the second quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 499 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Aimmune Therapeutics by 454.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 4,900 shares during the period. Legal & General Group Plc increased its stake in Aimmune Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 1,634 shares during the period. Voya Investment Management LLC increased its stake in Aimmune Therapeutics by 31.2% in the second quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 3,757 shares during the period. Finally, DekaBank Deutsche Girozentrale purchased a new stake in Aimmune Therapeutics during the second quarter valued at $333,000. 69.65% of the stock is currently owned by institutional investors.

In related news, insider Douglas T. Sheehy sold 7,460 shares of the firm’s stock in a transaction on Friday, July 21st. The stock was sold at an average price of $21.66, for a total transaction of $161,583.60. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Stephen George Dilly sold 49,400 shares of the firm’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $20.21, for a total value of $998,374.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 188,470 shares of company stock worth $3,942,092. Corporate insiders own 24.56% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Earnings History and Estimates for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.